|
GEN-009, a neoantigen vaccine containing ATLAS selected neoantigens, to generate broad sustained immunity against immunogenic tumor mutations and avoid inhibitory peptides. |
|
|
Consulting or Advisory Role - Alkermes; AstraZeneca; Cantargia AB; Genocea Biosciences; Heat Biologics; Innate Pharma; Kyn therapeutics; Takeda |
Research Funding - Celldex (Inst); Genocea Biosciences (Inst); Heat Biologics (Inst); Innate Pharma (Inst); Kyn therapeutics (Inst); Merck (Inst); Xencor (Inst) |
Travel, Accommodations, Expenses - Alkermes; Genocea Biosciences; Heat Biologics; Innate Pharma; Kyn therapeutics; Takeda |
|
|
Honoraria - Astellas Medivation; Bayer; Genentech/Roche; Janssen; Sanofi/Aventis |
Consulting or Advisory Role - Janssen; Sanofi/Aventis |
Speakers' Bureau - Astellas Pharma; Bayer; Genentech/Roche; Janssen; Sanofi |
|
|
Consulting or Advisory Role - Abbvie (Inst); Achilles Therapeutics (Inst); Association of Community Cancer Centers (ACCC) (Inst); Astellas Pharma (I); AstraZeneca (Inst); Atreca (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Otsuka (I); Pfizer (Inst); Ribon Therapeutics (Inst); Sanofi (Inst) |
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); Birdie (Inst); Boehringer Ingelheim (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neovia Oncology (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Shattuck Labs (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); University of Michigan (Inst); WindMIL (Inst) |
Travel, Accommodations, Expenses - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; EMD Serono; Exelixis; Genentech; Incyte; Janssen Oncology; Lilly; Merck; Novartis; Pfizer; Sanofi; Sysmex; Vapotherm |
|
|
Consulting or Advisory Role - BioMimetix; Bristol-Myers Squibb; EMD Serono; Genocea Biosciences; Merck; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Genocea Biosciences (Inst) |
|
|
Consulting or Advisory Role - Exelixis; Exelixis; Merck Sharp & Dohme |
Research Funding - Advaxis (Inst); Bristol-Myers Squibb (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst) |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Pfizer; Sanofi |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Pfizer |
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Pfizer; Sanofi |
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Pfizer |
|
|
No Relationships to Disclose |
|
|
Employment - Genocea Biosciences |
Stock and Other Ownership Interests - Genocea Biosciences |
Research Funding - Genocea Biosciences |
|
|
Employment - Genocea Biosciences |
Stock and Other Ownership Interests - Genocea Biosciences; Ipsen |
|
|
Employment - Genocea Biosciences |
Stock and Other Ownership Interests - Genocea Biosciences |
Travel, Accommodations, Expenses - Genocea Biosciences |
|
|
Stock and Other Ownership Interests - Genocea Biosciences |
|
|
Employment - Genocea Biosciences; Moderna Therapeutics (I) |
Stock and Other Ownership Interests - Genocea Biosciences; Moderna Therapeutics (I) |
Travel, Accommodations, Expenses - Genocea Biosciences; Moderna Therapeutics (I) |
|
|
Employment - DeCillis Consulting |
Leadership - DeCillis Consulting |
Stock and Other Ownership Interests - Exelis |
Consulting or Advisory Role - Arvinas; Codiak Biosciences; Cybrexa Therapeutics; CytomX Therapeutics; Daiichi Sankyo; Exelixis; Genocea Biosciences; Novartis; Pyramid Biosciences |
Patents, Royalties, Other Intellectual Property - Exelixis |
|
|
Employment - Genocea Biosciences |
Leadership - Genocea Biosciences |
Stock and Other Ownership Interests - Genocea Biosciences |
Research Funding - Genocea Biosciences |
Patents, Royalties, Other Intellectual Property - Momenta Pharmaceuticals |
Travel, Accommodations, Expenses - Genocea Biosciences |
|
|
Employment - Genocea Biosciences |
Leadership - Genocea Biosciences |
Stock and Other Ownership Interests - Genocea Biosciences |
Patents, Royalties, Other Intellectual Property - Genocea Biosciences |
|
|
Employment - Genocea Biosciences |
Leadership - Genocea Biosciences |
Stock and Other Ownership Interests - Genocea Biosciences |